Skip to main content

Table 5 Univariate and Multivariable analysis of factors potentially predictive of progress free interval

From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis

Characteristics

Total(N)

Univariate analysis

Multivariate analysis

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Age

1082

    

 <  = 60

601

Reference

   

 > 60

481

1.253 (0.904–1.738)

0.175

  

T stage

1079

    

T1

276

Reference

   

T2&T3&T4

803

1.886 (1.241–2.867)

0.003

1.609 (0.731–3.542)

0.237

N stage

1063

    

N0

514

Reference

   

N1&N2&N3

549

2.333 (1.621–3.357)

 < 0.001

1.771 (1.123–2.794)

0.014

M stage

922

    

M0

902

Reference

   

M1

20

8.315 (4.829–14.315)

 < 0.001

6.005 (3.115–11.573)

 < 0.001

Pathologic stage

1059

    

Stage I

180

Reference

   

Stage II&Stage III&Stage IV

879

2.268 (1.325–3.880)

0.003

0.867 (0.316–2.381)

0.782

ER status

1032

    

Negative

240

Reference

   

Positive

792

0.622 (0.436–0.887)

0.009

0.700 (0.394–1.244)

0.224

PR status

1029

    

Negative

342

Reference

   

Positive

687

0.558 (0.400–0.779)

 < 0.001

0.593 (0.343–1.025)

0.061

HER2 status

715

    

Negative

558

Reference

   

Positive

157

1.228 (0.712–2.119)

0.461

  

radiation_therapy

986

    

No

434

Reference

   

Yes

552

0.899 (0.631–1.281)

0.555

  

HSPB1

1082

    

Low

541

Reference

   

High

541

1.425 (1.137–1.750)

0.041

  
  1. TMN stage was according to the seventh edition of the Guidelines for the American Journal of Critical Care. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor. Bold values indicate that p < 0.05